RNA Hydrogel Combined with MnO 2 Nanoparticles as a Nano-Vaccine to Treat Triple Negative Breast Cancer

• Published in: Frontiers in chemistry 2021, Vol.9, p.797094
• Main Authors: Wang, Weicai, Liu, Xiaofan, Ding, Lairong, Jin, Hyung Jong, Li, Xuemei
• Format: Article
• Language: English
• ISSN: 2296-2646; 2296-2646
• DOI: 10.3389/fchem.2021.797094

Hypoxia is not only the reason of tumor metastasis but also enhances the spread of cancer cells from the original tumor site, which results in cancer recurrence. Herein, we developed a self-assembled RNA hydrogel that efficiently delivered synergistic DNA CpG and short hairpin RNA (shRNA) adjuvants, as well as MnO loaded-photodynamic agent chlorine e6 (MnO @Ce6), and a chemotherapy drug doxorubicin (DOX) into MDA-MB-231cells. The RNA hydrogel consists of one tumour suppressor miRNA (miRNA-205) and one anti-metastatic miRNA (miRNA-182), both of which showed an outstanding effect in synergistically abrogating tumours. The hydrogel would be dissociated by endogenous Dicer enzyme to release loaded therapeutic molecules, and in the meantime induce decomposition of tumor endogenous H O to relieve tumor hypoxia. As a result, a remarkable synergistic therapeutic effect is achieved through the combined chemo-photodynamic therapy, which simultaneously triggers a series of anti-tumor immune responses. Besides, the hydrogel as the carrier which modified aptamer to targeted MDA-MB-231 has the advantages of good biocompatibility and low cytotoxicity. This strategy could be implemented to design any other microRNA (miRNA) as the carrier, combined with other treatment methods to treat human cancer, thereby overcoming the limitations of current cancer therapies.